Haleon plc (HLN) Stock Analysis & Investment Frameworks
Haleon plc (HLN) stock analysis on Invetso. Review Haleon plc’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Haleon plc Company Overview
- Exchange: New York Stock Exchange
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: GB
Haleon plc Key Financial Metrics
- Market Cap: $40.24B
- Revenue: $14.78B
- P/E Ratio: 18.3
- ROE: 9.89%
- ROIC: 6.46%
- Dividend Yield: 2.21%
About Haleon plc
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
Haleon plc Investment Frameworks
Invetso analyzes Haleon plc (HLN) across the following frameworks:
- Haleon plc 10Y Growth Potential
- Haleon plc Scenario Analysis
- Haleon plc Risks & Opportunities
- Haleon plc Economic Moat
- Haleon plc Business Model
- Haleon plc Management
- Haleon plc SWOT Analysis
- Haleon plc Porter's 5 Forces
- Haleon plc PESTLE Analysis
- Haleon plc ESG Analysis